東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Incidence of Adverse Drug Events in ...

Patel, Purva.

Linked to FindBook

Google Book

Amazon

博客來

Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study./
Author:	Patel, Purva.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	48 p.
Notes:	Source: Masters Abstracts International, Volume: 82-12.
Contained By:	Masters Abstracts International82-12.
Subject:	Bioinformatics. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28542645
ISBN:	9798516069321

Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study.
Patel, Purva.

Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 48 p.

Source: Masters Abstracts International, Volume: 82-12.

Thesis (M.S.)--University of Missouri - Kansas City, 2021.

This item must not be sold to any third party vendors.

Pharmacovigilance is a crucial component of today's health science studies that allows researchers to detect, assess, understand, to ultimately prevent any adverse event associated with drugs. Today, with the world struggling to get the COVID-19 pandemic under control, it is important to look at how this disease is affecting different patient populations. A common complication associated with this disease is thrombosis. A lower mortality rate in COVID-19 patients has been related to the use of the drug heparin, a widely used anticoagulant. The main objective of this study was to assess whether there were any adverse events associated with the administration of anticoagulants in patients known to have COVID-19. Thus, it was hypothesized that with study of different anticoagulant drugs, there would be no significant difference in the observed adverse events for these drugs. Data for this study was obtained from a deidentified secondary database of COVID-19 positive patients from Truman Medical Center, Kansas City, MO and from the FDA's Adverse Event Reporting System (FAERS) Public Database. Chi-square test of association was performed to determine associations of race, sex and hospitalization rate with the adverse outcome variables. Proportional Reporting Ratios (PRR) and lower 95% confidence intervals (Lower CI) were calculated for data from the FAERS database where the adverse events studied, mimicked COVID-19 symptoms. It was found that there is a significant association between race and hospitalization rate for patients who were on anticoagulants and had COVID-19. Additionally, the study results suggested that patients who were put on the anticoagulant heparin were more likely to develop pneumonia compared to other anticoagulating drugs. However, no reportable adverse drug event was found for any other selected anticoagulant drugs. Given the findings, it would be important for the clinicians to use heparin with caution, especially in COVID-19 patients.

ISBN: 9798516069321Subjects--Topical Terms:

553671
Bioinformatics.
Subjects--Index Terms:

Adverse drug events

Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study.
LDR:03107nmm a2200349 4500 001 2282096
005 20210927083539.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798516069321
035 $a (MiAaPQ)AAI28542645
035 $a AAI28542645
040 $a MiAaPQ $c MiAaPQ
100 1 $a Patel, Purva. $3 3560844
245 1 0 $a Incidence of Adverse Drug Events in COVID-19 Patients on Anticoagulants: A Pharmacovigilance Study.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 48 p.
500 $a Source: Masters Abstracts International, Volume: 82-12.
500 $a Advisor: Gaddis, Monica.
502 $a Thesis (M.S.)--University of Missouri - Kansas City, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Pharmacovigilance is a crucial component of today's health science studies that allows researchers to detect, assess, understand, to ultimately prevent any adverse event associated with drugs. Today, with the world struggling to get the COVID-19 pandemic under control, it is important to look at how this disease is affecting different patient populations. A common complication associated with this disease is thrombosis. A lower mortality rate in COVID-19 patients has been related to the use of the drug heparin, a widely used anticoagulant. The main objective of this study was to assess whether there were any adverse events associated with the administration of anticoagulants in patients known to have COVID-19. Thus, it was hypothesized that with study of different anticoagulant drugs, there would be no significant difference in the observed adverse events for these drugs. Data for this study was obtained from a deidentified secondary database of COVID-19 positive patients from Truman Medical Center, Kansas City, MO and from the FDA's Adverse Event Reporting System (FAERS) Public Database. Chi-square test of association was performed to determine associations of race, sex and hospitalization rate with the adverse outcome variables. Proportional Reporting Ratios (PRR) and lower 95% confidence intervals (Lower CI) were calculated for data from the FAERS database where the adverse events studied, mimicked COVID-19 symptoms. It was found that there is a significant association between race and hospitalization rate for patients who were on anticoagulants and had COVID-19. Additionally, the study results suggested that patients who were put on the anticoagulant heparin were more likely to develop pneumonia compared to other anticoagulating drugs. However, no reportable adverse drug event was found for any other selected anticoagulant drugs. Given the findings, it would be important for the clinicians to use heparin with caution, especially in COVID-19 patients.
590 $a School code: 0134.
650 4 $a Bioinformatics. $3 553671
650 4 $a COVID-19. $3 3554449
653 $a Adverse drug events
653 $a COVID-19
653 $a Patients
653 $a Anticoagulants
653 $a Pharmacovigilance
690 $a 0715
710 2 $a University of Missouri - Kansas City. $b Bioinformatics. $3 3560845
773 0 $t Masters Abstracts International $g 82-12.
790 $a 0134
791 $a M.S.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28542645